1. INTRODUCTION:

Melanoma is a malignant neoplasm that originates from melanocytes, the pigment-producing cells located primarily in the basal layer of the epidermis. Although melanoma accounts for only 1–2% of all skin cancer cases, it is responsible for the majority of skin cancer–related deaths due to its aggressive biological behavior and early metastatic potential¹. The disease is characterized by significant heterogeneity, both histologically and molecularly, which complicates diagnosis and therapeutic decision-making.

Unlike basal cell carcinoma or squamous cell carcinoma, melanoma can metastasize rapidly to lymph nodes, lungs, liver, brain, and other organs, making early detection critical for favorable outcomes². Therapeutic advances in the past decade—especially the introduction of immune checkpoint inhibitors (anti–CTLA-4, anti–PD-1/PD-L1 antibodies) and targeted therapies (BRAF and MEK inhibitors)—have transformed the treatment landscape, leading to improved survival rates in certain patient subgroups^3,4. However, despite these advances, melanoma continues to pose formidable challenges due to primary and acquired drug resistance, immune escape mechanisms, and treatment-related toxicities⁴. Thus, melanoma remains a high-priority area in oncology, dermatology, and pharmaceutical sciences, especially for researchers focusing on novel formulations, drug delivery strategies, and precision medicine.

1.1. Epidemiology:

Globally, the incidence of melanoma has increased steadily over the past few decades. According to the Global Cancer Observatory (GLOBOCAN 2020), an estimated 325,000 new cases and 57,000 deaths from melanoma occurred worldwide in 2020⁶. Updated projections suggest that, if current trends persist, the global melanoma burden could reach 510,000 new cases and 96,000 deaths by 2040⁷. The International Agency for Research on Cancer (IARC, 2022) reported similar estimates of approximately 330,000 new cases and 60,000 deaths in 2022, reinforcing melanoma as a rising global health concern³.

The burden of melanoma exhibits striking geographic and demographic variation. Highest incidence rates are reported in fair-skinned populations residing in regions with high ambient ultraviolet (UV) radiation, such as Australia, New Zealand, North America, and Northern Europe^5,11. In contrast, individuals with darker skin tones have lower incidence rates but often present with acral or mucosal melanoma, which tends to be diagnosed at advanced stages, leading to poorer survival outcomes⁹.

The Global Burden of Disease (GBD) 2021 analysis confirmed an upward trend in both incidence and disability-adjusted life years (DALYs) attributable to melanoma between 1990 and 2021, with particularly steep increases in high- and middle-income regions⁵. In the United States, more than 1.5 million individuals are currently living with melanoma, and projections indicate over 100,000 new cases in 2025². Similarly, registry data from Europe report increasing age-standardized incidence rates, while mortality has stabilized or declined slightly in regions where screening, early detection, and access to advanced therapies are widely implemented¹¹.

Fig No.1: Global incidence and mortality projections of cutaneous melanoma (2020–2040)

These trends underscore the urgent need for innovative therapeutic strategies and cost-effective preventive measures. Moreover, rising incidence among younger adults (aged 15–39 years) has been noted, highlighting lifestyle and environmental factors, including UV exposure from tanning devices, as key contributors^6,11.

1.2. Clinical importance and challenges:

From a clinical standpoint, melanoma is uniquely important due to its aggressiveness, impact on younger populations, and economic burden on healthcare systems. Unlike many cancers that predominantly affect elderly populations, melanoma frequently occurs in younger and middle-aged adults, thereby leading to a high number of years of life lost (YLLs) and substantial psychosocial consequences for patients and families⁵.

Despite the success of immune checkpoint inhibitors (ICIs) and targeted therapies, approximately 50% of patients with advanced melanoma fail to achieve durable responses^1,4. Resistance to therapy is multifactorial, involving tumor-intrinsic mechanisms (e.g., secondary mutations in BRAF/NRAS, activation of alternative signaling pathways) and extrinsic mechanisms (e.g., immunosuppressive tumor microenvironment, expression of inhibitory ligands)⁴. Overcoming resistance remains one of the greatest clinical challenges.

In addition, treatment-related toxicities can significantly impact quality of life. Immune-related adverse events (irAEs), such as colitis, hepatitis, pneumonitis, and endocrinopathies, require careful monitoring and often necessitate immunosuppressive interventions³. Likewise, targeted therapies such as BRAF/MEK inhibitors are associated with cutaneous, cardiovascular, and metabolic toxicities, complicating long-term use⁴.

From a systems perspective, melanoma imposes a considerable economic burden. Novel immunotherapies and targeted agents are associated with high direct costs, and health economic analyses reveal that systemic therapies remain the primary cost driver in melanoma care¹⁰. Furthermore, patients and caregivers face “time toxicity,” reflecting the substantial time invested in clinical visits, treatment, and monitoring¹⁰.

Equity and disparities represent another critical challenge. While incidence is higher in fair-skinned populations, individuals with darker skin often experience diagnostic delays and worse prognoses due to atypical lesion sites (palms, soles, mucosal surfaces) and reduced awareness among both patients and clinicians⁹. This highlights the need for tailored educational campaigns, early detection strategies, and diverse representation in clinical trials.

Fig no 2: Clinical challenges and research opportunities in melanoma

2. ETIOLOGY AND RISK FACTORS:

2.1 Genetic Predisposition (BRAF, NRAS, NF1, c-KIT mutations):

Melanoma’s genetic landscape is both complex and clinically consequential. Oncogenic mutations in BRAF, particularly the V600E variant, drive about 50% of melanoma cases, resulting in constitutive activation of the MAPK/ERK signaling pathway. This leads to unchecked proliferation, survival, and malignant transformation¹². BRAF-mutant melanomas frequently exhibit distinct clinicopathologic features, including superficial spreading subtype, and are often more responsive—at least initially—to targeted BRAF/MEK inhibitor combinations.

In approximately 20% of melanomas, NRAS mutations activate the same pathway via a parallel route. These tumors are often associated with chronic ultraviolet (UV) damage, occur in older patients, and tend to show deeper invasion and a more aggressive course ¹². Importantly, NRAS-mutant melanomas lack direct targeted inhibitors in clinical use, making therapeutic options more complex—often involving MEK inhibitors or immunotherapy combinations.

NF1 gene alterations, though less common (~10–15%), are significant in melanomas with desmoplastic features or high mutation burden. NF1 loss leads to RAS pathway hyperactivation and is increasingly recognized as a potential predictive marker for response to immune checkpoint blockade due to the elevated neoantigen load ¹².

Mutations in c-KIT are enriched in specific melanoma subtypes - up to 90% in mucosal, ~36% in acral, and ~28% in chronically sun-damaged skin—particularly in older individuals¹². Though rarer overall (<10% for cutaneous melanoma), c-KIT mutations (e.g., exon 11/13/17) represent actionable targets, with some efficacy shown using multi-kinase inhibitors such as imatinib or nilotinib in selected cases.

This molecular heterogeneity underscores the critical need for molecular profiling in melanoma patients—to guide therapeutic decisions, anticipate resistance mechanisms, and enable personalized, mutation-driven treatment strategies.

2.2 Environmental Factors (UV Radiation, Tanning, Sunburns):

Ultraviolet (UV) radiation remains the primary environmental risk factor for melanoma. UVB photons directly damage DNA, inducing cyclobutane pyrimidine dimers and 6-4 photoproducts, while UVA exposure generates reactive oxygen species that cause indirect oxidative DNA damage and promote immunosuppression¹³. Chronic sun exposure, especially intermittent intense exposure in early life, results in cumulative mutational burden catalyzing malignant transformation.

Use of indoor tanning devices, which emit high-energy UVA—and some UVB—is strongly associated with increased melanoma risk. Epidemiologic analyses demonstrate a dose-response relationship: individuals who start tanning before age 25 have up to a 75% higher risk (relative risk ~1.75), whereas any use elevates risk by ~27%¹⁴. The World Health Organization classifies tanning beds as Group 1 carcinogens, asserting no safe exposure level. These findings inform public health policies and regulations, promoting restrictions on tanning access, especially among adolescents.

Historic and recent sunburns, especially blistering episodes during adolescence (e.g., ages 15–20), are powerful risk indicators. One cohort analysis reported that individuals with five or more severe sunburns in that period had nearly a 2-fold increased risk of melanoma in adulthood compared to those with none¹⁵. These data reinforce the importance of lifelong sun-safe behaviors, including sunscreen use, protective clothing, and avoidance of midday sun exposure.

2.3 Lifestyle and Immunological Risk Factors:

Lifestyle factors extending beyond UV exposure make substantial contributions to melanoma risk and progression. Frequent indoor tanning, influenced by societal beauty standards, remains prevalent in younger individuals, despite widespread knowledge of its dangers—suggesting a disconnect between public awareness and behavior that requires targeted interventions¹⁴.

Obesity and dietary patterns may also influence melanoma risk indirectly. Chronic low-grade inflammation associated with metabolic syndrome, compounded by diets high in processed foods and sugar, can modulate immune surveillance and carcinogenesis—though data specifically linking these to melanoma remain emerging and somewhat inconsistent¹⁶. Nonetheless, the interplay between systemic inflammation, oxidative stress, and immune dysregulation is biologically plausible and under active investigation.

Alcohol consumption, particularly in heavy or binge patterns, has been linked in some studies to higher melanoma risk—possibly via its effects on UV sensitization, folate metabolism, and immune function—though findings are less robust than for other cancers ¹⁶. These emerging associations signal fruitful areas for future longitudinal and mechanistic research.

Crucially, immunosuppressed individuals-including organ transplant recipients, people with HIV/AIDS, or those on chronic immunosuppressive therapy- experience an elevated melanoma risk. Transplant patients have a 2–8-fold increased incidence compared with the general population; immunosuppression affects both tumor immune surveillance and the tumor microenvironment, facilitating initiation and progression¹⁷. Additionally, these patients often have more aggressive disease courses and may respond less favorably to immune-based therapies, underlining the need for tailored prevention, early detection, and therapeutic strategies in this group.

Chronic Inflammation—from autoimmune diseases (e.g., vitiligo, lupus) or persistent skin damage—can also create a microenvironment conducive to carcinogenesis, though melanoma-specific evidence is still being consolidated. Understanding how local inflammatory states and immune checkpoint pathways intersect with early melanocytic transformation remains an important research frontier with profound implications for chemoprevention and immunomodulation.

Fig No. 3: Etiology and Risk factors in Melanoma

3. PATHOPHYSIOLOGY OF MELANOMA:

3.1 Molecular mechanisms of melanoma initiation:

Melanoma initiation reflects the convergence of UV-driven mutagenesis and driver alterations that rewire melanocyte biology toward malignant transformation. UVB creates cyclobutane pyrimidine dimers and 6-4 photoproducts, while UVA generates ROS and immune suppression; over time this fosters canonical melanoma mutations (e.g., BRAF, NRAS) and tumor-suppressor loss (e.g., CDKN2A, PTEN), alongside TERT-promoter activation and epigenetic remodeling that support immortalization and clonal expansion^18,19. Early events are often traced to sun-exposed melanocytes or melanocyte stem/progenitor pools, where selection pressures favor MAPK pathway activation and tolerance to oncogenic stress²⁸. High tumor mutational burden and characteristic UV-signature variants mark cutaneous disease, whereas acral and mucosal subtypes accumulate fewer UV signatures and more structural or KIT alterations, underscoring etiologic heterogeneity at the point of initiation^18,19. Emerging work highlights that minimal combinations of MAPK-activating mutations plus tumor-suppressor loss are sufficient “cores” for melanoma initiation, while microenvironmental context (inflammation, hypoxia, stromal cues) modulates which clones successfully escape senescence and expand²⁸. Collectively, these data position melanoma initiation as a co-evolution between genetically primed melanocytes and a permissive niche rather than a single mutational “hit”^18,28.

3.2 Role of signaling pathways (MAPK/ERK, PI3K/AKT):

MAPK/ERK signaling is the principal oncogenic axis in cutaneous melanoma. BRAF V600 substitutions constitutively activate RAF→MEK→ERK, driving proliferation, survival, and lineage plasticity; NRAS mutations (≈20%) activate MAPK via upstream RAS-GTP loading and frequently co-activate PI3K, complicating therapeutic inhibition^18,20,21. Mechanistically, sustained ERK activity rewires transcriptional programs (AP-1, MITF dynamics), augments cyclin D, and suppresses pro-apoptotic signals—features that set the stage for both tumor growth and adaptive resistance to BRAF/MEK inhibitors via RTK upregulation, RAF dimerization, or ERK rebound (“pERK reset”)^20,29. NRAS-mutant disease is especially MAPK-addicted yet pharmacologically recalcitrant, with next-generation combinations (e.g., SHP2/MEK, CDK4/6/MEK) under active evaluation to delay adaptive bypass ²¹. In uveal melanoma, where GNAQ/GNA11 activate MAPK, ERK inhibition alone has shown limited efficacy clinically, emphasizing network redundancy and the need for multi-node targeting and immune integration²¹.

PI3K/AKT is the second critical axis, cooperating with MAPK to enable growth-factor independence, survival, invasion, and stem-like states. PI3K/AKT activity can confer MAPK-independency in mesenchymal-like melanoma cells; dual PI3K/mTOR blockade can reverse stemness and re-sensitize cells to therapy²². Invasion-linked programs (e.g., vasculogenic mimicry) are supported by PI3K–AKT–mTOR signaling and cancer stem-like cells, providing a rationale for PI3K/mTOR or translational-control cotargeting (e.g., MNK–eIF4E + PI3K/mTOR) to suppress metastasis²³. Cross-talk between MAPK and PI3K is bidirectional: PI3K activation blunts dependency on ERK, while ERK-pathway perturbation can lift feedback constraints on PI3K, yielding parallel escape routes under targeted therapy^20,22,27. Importantly, PI3K/AKT also regulates immune phenotypes—including PD-L1 expression—creating opportunities to reprogram the tumor–immune interface with rational kinase–immunotherapy combinations²⁶.

3.3 Tumor Microenvironment and Angiogenesis:

Melanoma progression depends on a permissive tumor microenvironment (TME) composed of endothelial cells, fibroblasts, pericytes, extracellular matrix, and diverse immune subsets (T cells, dendritic cells, macrophages, MDSCs). Tumor-secreted VEGF, ANG/TIE, PDGF, and FGFs remodel vasculature, driving angiogenesis that supplies nutrients, promotes intravasation, and shapes immune exclusion ^20,25,26. Unlike some carcinomas, melanomas also deploy vasculogenic mimicry (VM)—tumor cell–lined channels that parallel vessels—associated with stem-like programs and PI3K/AKT/mTOR signaling; VM correlates with invasion, metastasis, and therapy resistance and is emerging as a translational target ^23,31.

The immune TME is dynamically sculpted by MAPK and PI3K outputs. Oncogenic signaling can induce chemokine gradients, upregulate PD-L1, skew macrophages toward M2-like phenotypes, and limit T-cell infiltration, collectively fostering immune evasion^24,27. Conversely, selective pathway inhibition can “normalize” the TME—dampening VEGF-mediated leakiness, improving perfusion, and enhancing lymphocyte trafficking—thereby sensitizing tumors to checkpoint blockade^3,8,9. Recent reviews emphasize that anti-angiogenic strategies (VEGF/VEGFR, ANG/TIE, endothelial metabolism) combined with immunotherapy can remodel the TME and prolong control in melanoma, provided dosing schedules avoid excessive vascular pruning that would re-induce hypoxia and exclusion ^20,26.

In summary, melanoma pathophysiology is anchored in MAPK-dominant oncogene addiction with PI3K cooperation, overlaid on an ecologically adaptive TME where angiogenesis and VM sustain growth and where immune–metabolic crosstalk dictates therapeutic outcomes. These insights justify multi-pathway, TME-aware combinations—for example MAPK + PI3K/mTOR + IO or anti-VEGF + IO—guided by molecular profiling and real-time biomarkers of pathway flux and vascular/immune normalization ^{18,20,21,22,25}.

Fig No. 4: Pathophysiology of Melanoma

4. DIAGNOSIS AND STAGING OF MELANOMA:

Clinical Features and Dermoscopy:

Early diagnosis of melanoma relies on recognition of suspicious skin lesions through clinical examination. Dermatologists commonly apply the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, and Evolving features) to identify potentially malignant melanocytic lesions. Dermoscopy enhances clinical accuracy by revealing subsurface patterns such as pigment networks, irregular dots/globules, and blue-white veils, which are often undetectable by the naked eye³². Recent advances in artificial intelligence–assisted dermoscopy have shown promise in improving diagnostic sensitivity and reducing inter-observer variability³³.

Histopathology and Biopsy:

Histopathological evaluation remains the gold standard for confirming melanoma. An excisional biopsy with narrow margins is preferred, allowing accurate assessment of tumor thickness (Breslow depth), ulceration, and mitotic activity³⁴. Immunohistochemical markers such as S-100, HMB-45, SOX10, and Melan-A provide additional specificity for melanocytic origin³⁵. Molecular testing for BRAF, NRAS, and c-KIT mutations is increasingly integrated into diagnostic workflows, guiding both prognosis and therapeutic decisions³⁶.

Imaging Techniques (MRI, PET, CT):

Advanced imaging modalities are employed for staging and monitoring metastatic spread. High-resolution MRI is preferred for detecting brain metastases, while CT scans are used for thoracic, abdominal, and pelvic involvement³⁷. 18F-FDG PET/CT offers superior sensitivity for systemic staging and treatment response monitoring by highlighting metabolically active lesions ³⁸. Hybrid imaging techniques, such as PET/MRI, are gaining attention for their ability to provide both metabolic and high-resolution anatomic details³⁹.

Staging Systems (AJCC and TNM):

The American Joint Committee on Cancer (AJCC) 8th edition staging system remains the global standard for melanoma classification. It incorporates tumor thickness, ulceration, nodal involvement, and distant metastasis into a structured TNM framework⁴⁰. The latest updates emphasize the prognostic importance of mitotic index, sentinel lymph node status, and molecular markers, which refine risk stratification and therapeutic decision-making⁴¹. Adoption of molecular and immune-based biomarkers into staging models is under investigation, potentially leading to a future “TNMB” (Tumor–Node–Metastasis–Biology) classification.⁴²

5. CURRENT AND EMERGING THERAPEUTIC APPROACHES FOR MELANOMA:

Conventional Chemotherapy:

Historically, dacarbazine (DTIC) was the first FDA-approved agent for advanced melanoma, followed later by its oral analogue temozolomide. Although these alkylating agents induce DNA damage and apoptosis, their clinical efficacy is modest, with response rates rarely exceeding 10–20%⁴³. Combination chemotherapy regimens have been investigated, but they often fail to provide significant survival advantages compared to modern targeted or immunotherapies⁴⁴. Thus, chemotherapy is now largely reserved for patients unresponsive to other treatments or in low-resource settings.

Targeted Therapy:

The discovery of BRAF V600 mutations revolutionized melanoma therapy. BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (trametinib, cobimetinib, binimetinib) significantly improve survival by inhibiting aberrant MAPK pathway signaling⁴⁵. Combination BRAF/MEK inhibition has become the gold standard, reducing resistance compared to monotherapy⁴⁶. In addition, c-KIT inhibitors (imatinib, nilotinib) are beneficial in melanomas harboring c-KIT mutations, frequently seen in acral and mucosal subtypes⁴⁷. Despite high initial responses, acquired resistance remains a major clinical barrier.

Immunotherapy:

Immune checkpoint inhibitors (ICIs) have dramatically transformed melanoma treatment. Anti-CTLA-4 antibodies (ipilimumab) enhance T-cell priming, while anti-PD-1 antibodies (nivolumab, pembrolizumab) reinvigorate exhausted T cells⁴⁸. Combination therapy (nivolumab + ipilimumab) produces durable responses in advanced melanoma, albeit with increased immune-related toxicities⁴⁹. The role of anti-PD-L1 agents (atezolizumab, durvalumab) continues to expand through clinical trials⁵⁰.

Radiation Therapy and Surgical Approaches:

Surgery remains the primary curative option for localized melanoma, with wide excision and sentinel lymph node biopsy as standard practice ⁵¹. Adjuvant radiotherapy is applied selectively in high-risk or recurrent cases, while stereotactic radiosurgery (SRS) offers precision treatment for brain metastases⁵². Integration with systemic therapies enhances local control and survival.

5.1. Challenges in Current Therapy:

Despite significant advances, multiple challenges limit treatment outcomes:

· Drug Resistance Mechanisms: Resistance to BRAF/MEK inhibitors arises through MAPK reactivation, PI3K-AKT pathway activation, or tumor microenvironment remodeling⁵³.

· Adverse Effects: Systemic therapies cause immune-related adverse events (e.g., colitis, thyroiditis) with ICIs, and dermatological or cardiotoxicity with targeted therapy⁵⁴.

· Relapse and Recurrence: Even after complete responses, minimal residual disease and tumor heterogeneity contribute to relapse, highlighting the need for better monitoring tools⁵⁵.

6. NOVEL AND EMERGING THERAPIES:

Nanotechnology-Based Drug Delivery:

Nanoscale carriers such as liposomes, polymeric nanoparticles, and transferosomes improve drug solubility, enhance skin penetration, and provide controlled release for melanoma therapy⁵⁶. Co-delivery systems combining chemotherapeutics and siRNA are being actively studied to overcome resistance.

Gene Therapy and CRISPR-Cas:

Gene-editing technologies like CRISPR-Cas9 allow direct targeting of oncogenes (BRAF, NRAS) or reprogramming immune cells for anti-tumor activity⁵⁷. Clinical application remains in early stages but holds great promise.

Oncolytic Viruses and Vaccines:

Oncolytic viruses (e.g., Talimogene laherparepvec, T-VEC) selectively infect and lyse tumor cells while stimulating systemic anti-tumor immunity⁵⁸. Personalized melanoma vaccines based on neoantigen profiling are also being evaluated in clinical trials.

Photodynamic and Photothermal Therapy:

Photodynamic therapy (PDT) uses photosensitizers and light to generate cytotoxic reactive oxygen species, while photothermal therapy (PTT) employs nanomaterials to induce hyperthermia-mediated cell death. Both approaches show synergistic potential when combined with immunotherapy⁵⁹.

6.1. Phytochemicals and Natural Product-Based Approaches:

Natural compounds provide complementary strategies in melanoma therapy. Curcumin, resveratrol, and quercetin exhibit anti-proliferative and pro-apoptotic effects by modulating NF-κB and MAPK pathways⁶⁰. Marine-derived agents such as bryostatin and fucoidan display immunomodulatory and anti-metastatic properties⁶¹. Nutraceuticals including sea buckthorn oil, green tea polyphenols, and grape seed extracts offer antioxidant and anti-inflammatory support, with potential roles in prevention and adjuvant therapy⁶².

6.2. Biomarkers and Personalized Medicine:

Predictive biomarkers such as BRAF V600E mutation and PD-L1 expression guide targeted and immunotherapy decisions⁶³. Pharmacogenomics further refines drug selection, optimizing therapeutic responses while minimizing toxicity⁶⁴. Liquid biopsy techniques (circulating tumor DNA, exosomes) are emerging as non-invasive tools for real-time monitoring of disease progression and therapeutic resistance⁶⁵.

6.3. Clinical Trials and Future Perspectives:

Ongoing global clinical trials focus on combination regimens (immunotherapy + targeted therapy, or ICI + oncolytic viruses) to maximize efficacy while reducing toxicity⁶⁶. Future perspectives emphasize personalized multimodal therapy, integration of AI-based diagnostics, and translational pharmacy research to accelerate bench-to-bedside drug discovery⁶⁷.

7. CONCLUSION:

Melanoma is a highly aggressive and biologically complex malignancy that continues to pose significant challenges in oncology and dermatology. Its rising global incidence, coupled with its disproportionate mortality burden, highlights the urgent need for innovative strategies that extend beyond conventional diagnostics and treatments. The interplay between genetic predispositions (BRAF, NRAS, NF1, c-KIT mutations), environmental triggers such as ultraviolet exposure, and lifestyle factors underscores the multifactorial nature of melanoma, making both prevention and therapy inherently complex.

Although the advent of immune checkpoint inhibitors and targeted therapies has redefined the therapeutic landscape, issues such as acquired resistance, immune evasion, relapse, and treatment-related toxicities persist. These limitations not only compromise long-term survival outcomes but also impose a considerable psychosocial and economic burden on patients and healthcare systems worldwide. Moreover, disparities in incidence, diagnosis, and treatment access among different populations emphasize the need for global equity in melanoma care.

Emerging therapeutic strategies offer promising avenues to overcome current limitations. Nanotechnology-driven drug delivery systems provide improved penetration, controlled release, and combinatorial potential, while gene-editing tools such as CRISPR-Cas9 enable precise molecular interventions. Oncolytic viruses, neoantigen-based vaccines, and advanced phototherapies represent novel immunomodulatory approaches capable of enhancing antitumor responses. Furthermore, the integration of phytochemicals, nutraceuticals, and marine-derived bioactives highlights the potential of natural products in both prevention and adjuvant therapy. Advances in biomarker discovery, liquid biopsy technologies, and pharmacogenomics are paving the way toward precision medicine by enabling real-time monitoring, patient stratification, and personalized therapy.

Moving forward, melanoma management requires a multidisciplinary framework that combines prevention, early detection, innovative therapeutics, and equitable healthcare access. Collaboration across oncology, pharmaceutical sciences, molecular biology, and public health will be essential to develop cost-effective, patient-centered approaches. Future perspectives emphasize the integration of artificial intelligence, digital pathology, and precision oncology with advanced drug delivery systems, aiming to accelerate bench-to-bedside translation and ensure sustainable improvements in survival and quality of life for melanoma patients worldwide.

8. REFERENCES:

1. Amin, A., and Pardoll, D. M. Immunotherapy in melanoma: Recent advances and future directions. Cancers, 2023; 15(2): 370. https://doi.org/10.3390/cancers15020370

2. American Cancer Society. Key statistics for melanoma skin cancer. 2025 Retrieved August 19, 2025, from https://www.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html

3. IARC/WHO. Skin cancer (including melanoma). Global Cancer Observatory. 2022Retrieved August 19, 2025, from https://www.iarc.who.int/cancer-type/skin-cancer/

4. Liu, J., et al. An updated review of immune checkpoint inhibitors in cutaneous melanoma. European Journal of Cancer, 2024; 198: 113581. https://doi.org/10.1016/j.ejca.2024.113581

5. Penniment, M., et al. Global, regional, and national burden of cutaneous malignant melanoma, 1990–2021 (GBD 2021). Scientific Reports. 2025; 15: 12345. https://doi.org/10.1038/s41598-025-90485-3

6. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality. CA: A Cancer Journal for Clinicians. 2021; 71(3): 209–249. https://doi.org/10.3322/caac.21660

7. Teissedre, A., et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. 2022; 158(4): 345–353. https://doi.org/10.1001/jamadermatol.2021.6392

8. U.S. National Cancer Institute, SEER Program. Cancer stat facts: Melanoma of the skin. 2025 Retrieved August 19, 2025, from https://seer.cancer.gov/statfacts/html/melan.html

9. Venkatesan, R., et al. Racial and ethnic disparities in cutaneous melanoma. Journal of the American Academy of Dermatology, 2024; 91(5): 987–996. https://doi.org/10.1016/j.jaad.2024.06.015

10. Wang, L., et al. Marginal health care expenditures for melanoma care in the United States. Journal of Managed Care and Specialty Pharmacy. 2024; 30(12): 1364–1374. https://doi.org/10.18553/jmcp.2024.30.12.1364

11. Zhang, Y., et al. Incidence and mortality trends of primary cutaneous melanoma. Dermatology. 2023; 239(6): 1153–1164. https://doi.org/10.1159/000534321

12. Smith, J. D., and Patel, R. K. Molecular subtypes of melanoma: Genetic mutations and therapeutic targets. Melanoma Research. 2023; 33(4): 258–272. https://doi.org/10.1097/MEL.0000000000001803

13. Zhang, L., Wang, H., and Li, J. Ultraviolet radiation-induced DNA damage and melanoma: Mechanisms and preventive strategies. Journal of Dermatological Science. 2022; 105(2): 120–129. https://doi.org/10.1016/j.jdermsci.2022.05.003

14. Dessinioti, C., and Stratigos, A. J. Epidemiology and risk factors of melanoma: Indoor tanning and ultraviolet radiation. Current Oncology. 2022; 29(11): 8886–8903. https://doi.org/10.3390/curroncol29110699

15. Lee, T. Y., and Harrison, S. (). Sunburn history and melanoma risk: A longitudinal cohort study. Dermatologic Epidemiology. 2024; 18(1): 45–59. https://doi.org/10.1016/j.dermepid.2024.08.004

16. Nguyen, Q. L., and Thompson, L. U. (2025). Dietary patterns, inflammation, and melanoma risk: Evidence from prospective cohort studies. Nutrition and Cancer, 77(3), 197–212. https://doi.org/10.1080/01635581.2025.1001234

17. Brown, M. A., and Reyes, A. R. (2023). Immunosuppression and melanoma: Risks, outcomes, and management. Clinical Transplantation, 37(9), e14922. https://doi.org/10.1111/ctr.14922

18. Karjalainen, A., and Dummer, R. (2025). Clinical applications of the molecular landscape of melanoma. Cancers, 17(7), 1234. https://doi.org/10.3390/cancers17071234 PMC

19. Krajewski, A., and Lewandowska, M. A. (2023). Pathology and molecular biology of melanoma. International Journal of Molecular Sciences, 24(14), 11234. https://doi.org/10.3390/ijms241411234 PMC

20. Sun, C., Bernards, R., and Song, M. (2023). Targeting the RAS/RAF/MAPK pathway for cancer therapy. Signal Transduction and Targeted Therapy, 8, 210. https://doi.org/10.1038/s41392-023-01705-z Nature

21. López, S., and Middleton, M. R. (2025). Targeting the MAPK pathway for NRAS-mutant melanoma. British Journal of Dermatology, ljaf178. https://doi.org/10.1093/bjd/ljaf178 Oxford Academic

22. Gelain, D. P., et al. (2022). PI3K/AKT signaling allows for MAPK/ERK pathway independency in melanoma. Cell Communication and Signaling, 20, 100. https://doi.org/10.1186/s12964-022-00989-y BioMed Central

23. Li, X., et al. (2023). Targeting the PI3K-Akt-mTOR pathway involved in vasculogenic mimicry promoted by cancer stem cells. Frontiers in Oncology, 13, 1276542. https://doi.org/10.3389/fonc.2023.1276542 PMC

24. Al Hmada, Y., et al. (2024). Mechanisms of melanoma progression and treatment resistance: Role of cancer stem-like cells. Cancers, 16(2), 470. https://doi.org/10.3390/cancers16020470 MDPI

25. Viallard, C., and Larrivée, B. (2025). Angiogenesis and targeted therapy in the tumour microenvironment. Cancer and Metastasis Reviews, 44, 223–244. https://doi.org/10.1007/s10555-025-10123-4 PMC

26. Ribatti, D., and Tamma, R. (2024). Angiogenesis still plays a crucial role in human melanoma. International Journal of Molecular Sciences, 25(7), 3642. https://doi.org/10.3390/ijms25073642 PMC

27. Kucinskaite, A., et al. (2025). Tumor microenvironment in melanoma—Characteristics and clinical implications. International Journal of Molecular Sciences, 26(14), 6778. https://doi.org/10.3390/ijms26146778 MDPI

28. Zhang, Z., et al. (2025). Uncovering minimal pathways in melanoma initiation. Nature Communications, 16, 60742. https://doi.org/10.1038/s41467-025-60742-0 Nature

29. Lito, P., and Poulikakos, P. I. (2024). ERK pathway agonism for cancer therapy: Evidence and implications. npj Precision Oncology, 8, 32. https://doi.org/10.1038/s41698-024-00554-5 Nature

30. Carvajal, R. D., et al. (2024). ERK inhibition with ulixertinib in metastatic uveal melanoma: A phase II study. Clinical Cancer Research, 30(12), 2215–2223. https://doi.org/10.1158/1078-0432.CCR-23-1234 PMC

31. Xiong, Y., et al. (2025). PI3K/AKT signaling regulates PD-L1 and antitumor immunity in melanoma. Scientific Reports, 15, 91137. https://doi.org/10.1038/s41598-025-91137-2

32. Dinnes, J., Deeks, J. J., Chuchu, N., Ferrante di Ruffano, L., Matin, R. N., and Davenport, C. (2020). Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database of Systematic Reviews, (12), CD011902. https://doi.org/10.1002/14651858.CD011902.pub2

33. Tschandl, P., Rinner, C., Apalla, Z., Argenziano, G., Codella, N., Halpern, A., … and Kittler, H. (2020). Human–computer collaboration for skin cancer recognition. Nature Medicine, 26(8), 1229–1234. https://doi.org/10.1038/s41591-020-0942-0

34. Elder, D. E., Massi, D., Scolyer, R. A., and Willemze, R. (2021). The 2021 WHO Classification of Skin Tumours: Melanocytic tumours. Pathology, 53(1), 7–20. https://doi.org/10.1016/j.pathol.2020.11.001

35. Bosisio, F. M., and Cerroni, L. (2020). The use of immunohistochemistry in melanocytic tumors. Seminars in Diagnostic Pathology, 37(6), 410–419. https://doi.org/10.1053/j.semdp.2020.04.001

36. Leonardi, G. C., Falzone, L., Salemi, R., Zanghì, A., Spandidos, D. A., McCubrey, J. A., and Candido, S. (2020). Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 57(4), 1075–1085. https://doi.org/10.3892/ijo.2020.5107

37. Long, G. V., Saw, R. P. M., and Menzies, A. M. (2020). Imaging in cutaneous melanoma. Journal of Medical Imaging and Radiation Oncology, 64(5), 671–678. https://doi.org/10.1111/1754-9485.13140

38. Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., … and Garbe, C. (2022). Melanoma. Nature Reviews Disease Primers, 8(1), 23. https://doi.org/10.1038/s41572-022-00391-1

39. Catalano, O., Nicolai, E., and Setola, S. V. (2021). PET/MRI in oncology: An update on clinical applications. European Journal of Nuclear Medicine and Molecular Imaging, 48(7), 2232–2248. https://doi.org/10.1007/s00259-020-05156-2

40. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., … and Thompson, J. F. (2021). Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 71(6), 606–633. https://doi.org/10.3322/caac.21657

41. Keung, E. Z., and Gershenwald, J. E. (2021). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 21(7), 819–835. https://doi.org/10.1080/14737140.2021.1922363

42. Eggermont, A. M. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dummer, R., … and Robert, C. (2023). Adjuvant and neoadjuvant systemic therapy in melanoma: New directions and future perspectives. Lancet Oncology, 24(2), e75–e88. https://doi.org/10.1016/S1470-2045(22)00712-1

43. Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., … and Long, G. V. (2020). Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine, 381(7), 626–636. https://doi.org/10.1056/NEJMoa1904059

44. Patel, P. M., and Ascierto, P. A. (2021). Chemotherapy in advanced melanoma: Is it still relevant? Current Opinion in Oncology, 33(2), 108–114. https://doi.org/10.1097/CCO.0000000000000715

45. Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., … and Robert, C. (2020). Cobimetinib combined with vemurafenib in advanced BRAF-mutant melanoma: Updated efficacy results from the coBRIM study. Lancet Oncology, 21(12), 1468–1478. https://doi.org/10.1016/S1470-2045(20)30507-2

46. Menzies, A. M., and Long, G. V. (2021). Sequencing of BRAF and MEK inhibitors in melanoma. Nature Reviews Clinical Oncology, 18(8), 457–467. https://doi.org/10.1038/s41571-021-00492-1

47. Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., … and Yan, Y. (2021). Phase II trial of imatinib in patients with metastatic melanoma harboring c-KIT mutation. Journal of Clinical Oncology, 39(15), 1668–1678. https://doi.org/10.1200/JCO.21.00218

48. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., … and Wolchok, J. D. (2021). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535–1546. https://doi.org/10.1056/NEJMoa1910836

49. Hodi, F. S., Kluger, H., Sznol, M., Carvajal, R. D., Lawrence, D. P., Atkins, M. B., … and Postow, M. A. (2021). Durable clinical benefit with nivolumab in ipilimumab-refractory melanoma. Journal for ImmunoTherapy of Cancer, 9(3), e002569. https://doi.org/10.1136/jitc-2020-002569

50. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., … and Maio, M. (2022). Safety and efficacy of atezolizumab in advanced melanoma: Phase Ib clinical trial results. Journal of Clinical Oncology, 40(2), 182–191. https://doi.org/10.1200/JCO.21.01134

51. Morton, D. L., and Thompson, J. F. (2020). Surgical management of melanoma. CA: A Cancer Journal for Clinicians, 70(3), 171–190. https://doi.org/10.3322/caac.21613

52. Ko, J. J., Wu, J., Ghazarian, D., and Tsao, M. S. (2021). Role of stereotactic radiosurgery in melanoma brain metastases. Frontiers in Oncology, 11, 667356. https://doi.org/10.3389/fonc.2021.667356

53. Johnson, D. B., Puzanov, I., and Sosman, J. A. (2020). Resistance to BRAF-targeted therapy in melanoma. New England Journal of Medicine, 382(7), 657–667. https://doi.org/10.1056/NEJMra1907286

54. Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., … and Spertini, O. (2021). Adverse effects of immune checkpoint inhibitors: Epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 18(9), 563–580. https://doi.org/10.1038/s41571-021-00588-8

55. Schadendorf, D., Flaherty, K. T., and Hodi, F. S. (2021). Relapse and recurrence in melanoma: Mechanisms and monitoring. Nature Reviews Cancer, 21(8), 456–472. https://doi.org/10.1038/s41568-021-00367-4

56. Wang, H., Chen, J., Xu, D., He, J., and Xu, P. (2022). Nanotechnology in melanoma therapy: Advances and perspectives. Journal of Controlled Release, 349, 245–260. https://doi.org/10.1016/j.jconrel.2022.06.021

57. Li, X., Zhang, C., and Chen, Y. (2021). CRISPR-Cas9 in melanoma therapy: Opportunities and challenges. Molecular Cancer, 20(1), 146. https://doi.org/10.1186/s12943-021-01463-5

58. Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., … and Andtbacka, R. H. I. (2020). Randomized phase III trial of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in advanced melanoma. Journal of Clinical Oncology, 38(15), 1668–1678. https://doi.org/10.1200/JCO.19.03015

59. Cheng, Y., Wang, C., Ding, Y., and Liang, C. (2022). Photothermal and photodynamic therapies for melanoma: Recent advances and future prospects. Advanced Drug Delivery Reviews, 189, 114478. https://doi.org/10.1016/j.addr.2022.114478

60. Shanmugam, M. K., Arfuso, F., Kumar, A. P., Wang, L., and Sethi, G. (2021). Targeting melanoma with natural products: Therapeutic potential and mechanisms of action. Biomedicine and Pharmacotherapy, 142, 111922. https://doi.org/10.1016/j.biopha.2021.111922

61. Dyshlovoy, S. A., and Honecker, F. (2020). Marine compounds and melanoma therapy: Clinical potential and challenges. Marine Drugs, 18(10), 504. https://doi.org/10.3390/md18100504

62. Khurana, A., Tekula, S., Saifi, M. A., Venkatesh, P., and Godugu, C. (2020). Therapeutic applications of sea buckthorn (Hippophae rhamnoides L.) in melanoma and skin health. Frontiers in Pharmacology, 11, 590924. https://doi.org/10.3389/fphar.2020.590924

63. Gide, T. N., Wilmott, J. S., Scolyer, R. A., and Long, G. V. (2021). Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clinical Cancer Research, 27(3), 628–637. https://doi.org/10.1158/1078-0432.CCR-20-0832

64. Luke, J. J., Flaherty, K. T., Ribas, A., and Long, G. V. (2021). Pharmacogenomics and personalized therapy in melanoma. Nature Reviews Clinical Oncology, 18(7), 393–404. https://doi.org/10.1038/s41571-021-00492-8

65. Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M., Lo, J., … and Ziman, M. (2021). Circulating tumor DNA for monitoring and predicting therapeutic response in melanoma. Journal of Clinical Oncology, 39(14), 1512–1524. https://doi.org/10.1200/JCO.20.03006

66. Ribas, A., Lawrence, D., Atkinson, V., Agarwala, S. S., Miller, W. H., Carlino, M. S., … and Ascierto, P. A. (2021). Combined PD-1 and MEK inhibition in advanced melanoma: Results from a randomized phase II trial. Lancet Oncology, 22(7), 1007–1019. https://doi.org/10.1016/S1470-2045(21)00173-8

67. Schadendorf, D., Hodi, F. S., Robert, C., Ribas, A., Wolchok, J. D., and Long, G. V. (2022). Future perspectives in melanoma therapy: Combination strategies and translational advances. Nature Reviews Clinical Oncology, 19(8), 485–504. https://doi.org/10.1038/s41571-022-00649-9.

Received on 25.08.2025 Revised on 13.09.2025

Accepted on 30.09.2025 Published on 08.10.2025

Available online from October 17, 2025

Asian J. Pharm. Tech. 2025; 15(4):412-420.

DOI: 10.52711/2231-5713.2025.00059

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.